Lung Cancer
The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.
Latest News
November 20th 2024
Osimertinib has been recommended for approval in patients with locally advanced, unresectable, EGFR-mutant NSCLC after chemoradiation.
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
More News
Repotrectinib Elicits Encouraging Response Rates in ROS1- and NTRK-Driven Tumors
Treatment with repotrectinib resulted in favorable responses in patients with ROS1- or NTRK-driven tumors, regardless of prior treatment with TKIs, according to interim data from the phase 2 TRIDENT-1 trial.
FDA Grants Durvalumab Priority Review for Fixed-Dose Use in NSCLC and Bladder Cancer
The FDA has granted a priority review designation to a supplemental biologics license application for a new 4-week, fixed-dose regimen as treatment in approved indications of non–small cell lung cancer and bladder cancer.
Experts Debate the Significance of ADAURA Data With Adjuvant Osimertinib in EGFR+ NSCLC
August 14th 2020The phase 3 ADAURA trial continues to generate a lot conversation, debate, and excitement in the lung cancer community after results showed that adjuvant osimertinib showed a statistically significant improvement in disease-free survival in patients with stage IB-IIIA EGFR-positive non–small cell lung cancer, making it the first agent to do so in the space.
Sequential Afatinib and Osimertinib Shows Continued OS Benefit in EGFR+ NSCLC
Treatment with afatinib followed by osimertinib resulted in a median overall survival benefit of almost 4 years in US patients with EGFR T790M–positive non–small cell lung cancer in the real-world setting.
